ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Cancer
Hematologic Cancer
Lymphoma
Recurrence
Leukemia
Smoldering Multiple Myeloma

Multiple Myeloma trials near New York, NY, USA:

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma (CarBiRD)

in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment with a combination of dru...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Clarithromycin

Phase 2

Weill Cornell Medicine (WCM)
Weill Cornell Medicine (WCM)

New York, New York, United States

of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple...

Active, not recruiting
Multiple Myeloma
Procedure: Stem Cell Mobilization
Drug: Bortezomib

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Morristown, New Jersey, United States and 7 other locations

multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: STI-6129

Phase 1, Phase 2

Sorrento Therapeutics
Sorrento Therapeutics

New York, New York, United States and 2 other locations

and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Talquetamab

Phase 2

Celgene
Celgene

New York, New York, United States and 24 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Isatuximab
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Hackensack, New Jersey, United States and 48 other locations

study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple...

Enrolling
Multiple Myeloma
Drug: Teclistamab
Drug: Mezigdomide

Phase 1

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 6 other locations

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma...

Begins enrollment this month
Relapsed or Refractory Multiple Myeloma
Drug: mRNA-2808

Phase 1, Phase 2

Moderna
Moderna

New York, New York, United States and 9 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Bendamustine
Drug: CC-95266

Phase 1

Juno Therapeutics

New York, New York, United States and 9 other locations

The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant...

Active, not recruiting
Multiple Myeloma
Biological: Ixazomib
Drug: Dexamethasone

Phase 2

The Washington University
The Washington University

New York, New York, United States and 9 other locations

this study will be to assess the efficacy and safety of treating elderly patients with relapsed/refractory multiple myeloma with a...

Enrolling
Multiple Myeloma in Relapse
Drug: Talquetamab
Drug: Daratumumab

Phase 2

Larysa Sanchez

New York, New York, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems